GeneTex
United States (US)

DR3 peptide

Cat No. GTX28445

Application Blocking
Species Human
APPLICATION

Application Note

The peptide is used for blocking the activity of DR3 (NT) (GTX28413). Incubatingthe peptide with equal volume of antibody for 30 min at 37ºC usually completely blocks theantibody activity in Western blotting.
PROPERTIES

Form

Liquid

Buffer

PBS pH7.2 with 10 mM NaH2PO4, 10 mM Na2HPO4, 130 mM NaCl, 0.1% bovine serum albumin, and 0.02% sodium azide

Storage

Store the peptide at -20˚C, stable for one year.

Concentration

0.20 mg/ml (Please refer to the vial label for the specific concentration.)

Conjugation

Unconjugated

Note

For laboratory use only. Not for any clinical, therapeutic, or diagnostic use in humans or animals. Not for animal or human consumption.
TARGET

Synonyms

Tnf Receptor Superfamily Member 25,Apo-3,Ddr3,Dr3,Lard,Tnfrsf12,Tr3,Tramp,Wsl-1,Wsl-Lr,Tnfrsf25

Background

Apoptosis, or programmed cell death, occurs during normal cellular differentiation and development of multicellular organisms. Apoptosis is induced by certain cytokines including TNF and Fas ligand of the TNF family, through their death domain containing receptors TNFR1 and Fas. A cell surface receptor with a death domain, DR3, has been identified by several groups independently, although it has been given alternative names. The ligand for DR3 has very recently been identified as TWEAK, also termed Apo-3L. DR3 is highly expressed in tissues enriched in lymphocytes including PBL, thymus and spleen. DR3 mediates activation of NF-kappa-B, and induces apoptosis. DR3 may also play a role in regulating lymphocyte homeostasis.

Research Area

Package List Price ($)
$ 179